Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding the molecular basis of HBV drug resistance by molecular modeling.

Antiviral research - 1 Dec 2008

Sharon Ashoke, Chu Chung K

Abstract excerpt

Despite the significant successes in the area of anti-HBV agents, resistance and cross-resistance against available therapeutics are the major hurdles in drug discovery. The present investigation is to understand the molecular basis of drug resistance conferred by the B and C domain mutations of HBV-polymerase on the binding affinity of five anti-HBV agents [lamivudine (3TC, 1), adefovir (ADV, 2), entecavir (ETV,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Discovery
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Products, pol

Share to Hepatitis B

Share to Hepatitis B virus

Share to Models, Molecular

Share to Protein Structure, Tertiary

Source

Open in PubMed Open full text

Identifiers

PMID: 18765256
DOI: 10.1016/j.antiviral.2008.07.010
PMCID: PMC2626186

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding the molecular basis of HBV drug resistance by molecular modeling.PMID 18765256Read ↗

Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.Semantic proximity Read ↗

Understanding the Genetics of Viral Drug Resistance by Integrating Clinical Data and Mining of the Scientific LiteratureSemantic proximity Read ↗

Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature.Semantic proximity Read ↗

Exploring the Drug Resistance of HCV Protease.Semantic proximity Read ↗

Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus InfectionsSemantic proximity Read ↗

First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients.Semantic proximity Read ↗

Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2.Semantic proximity Read ↗

Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.Semantic proximity Read ↗

Prediction and molecular field view of drug resistance in HIV-1 protease mutants.Semantic proximity Read ↗

Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling studySemantic proximity Read ↗

Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.